title: Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity.
abstract: Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7%-15%), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.
authors.affiliation: School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan.
authors.forename: Lu-Hsuan
authors.initials: LH
authors.lastname: Wu
authors.affiliation: School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; Health Outcome Research Center; and.
authors.forename: Yea-Huei Kao
authors.initials: YH
authors.lastname: Yang
authors.affiliation: Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan; and.
authors.forename: Chyi-Her
authors.initials: CH
authors.lastname: Lin
authors.affiliation: Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan; and.
authors.forename: Yuh-Jyh
authors.initials: YJ
authors.lastname: Lin
authors.affiliation: School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; Health Outcome Research Center; and clcheng@mail.ncku.edu.tw.
authors.forename: Ching-Lan
authors.initials: CL
authors.lastname: Cheng
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab / Q000009:adverse effects* / Q000627:therapeutic use; D004200:Diseases in Twins / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced* / Q000175:diagnosis; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D008297:Male; D012178:Retinopathy of Prematurity / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab